A novel peptide aldehyde with activity against human cytomegalovirus in two different in vivo models

Antiviral Chemistry and Chemotherapy

Volumn 11, Issue 1, 2000, Pages 51-59

  Weber, Olaf ^a   Reefschläger, Jürgen ^a   Rübsamen Waigmann, Helga ^a   Raddatz, Siegfried ^a   Hesseling, Matthias ^b   Häbich, Dieter ^a  

^a BAYER PHARMA AG   (Germany)

^b Bethesda Krankenhaus   (Germany)

Author keywords

Animal models; Human cytomegalovirus; Peptide aldehyde

Indexed keywords

2 (TERT BUTOXYCARBONYL) AMINO 1 PHENYL 1 OL; AGAROSE; ALDEHYDE; ANTIVIRUS AGENT; CIDOFOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; PA 8; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL TRANSPLANTATION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMAN TISSUE; KIDNEY FAILURE; MALE; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SPECIES DIFFERENCE;

EID: 17644449095     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020001100105     Document Type: Article

References (23)

1. Allen LB, Li S, Arnett G, Toyer B, Shannon WM & Hollingshead MG (1992) Novel method for evaluating antiviral drugs against human Cytomegalovirus in mice. Antimicrobial Agents and Chemotherapy 36:206-208.
2. Bitsch A, Kirchner H, Dupke R & Bein G (1993) Cytomegalovirus transcripts in peripheral blood leukocytes of actively infected transplant patients detected by reverse transcription-polymerase chain reaction. Journal of Infectious Diseases 167:740-743.
3. DiLoreto D, Epstein LG, Lazar ES, Britt WJ & Del Cerro M (1994) Cytomegalovirus infection of human retinal tissue: an in vivo model. Laboratory Investigations 71:141-148.
4. Drew WL, Miner RC, Busch DF, Follandsbee SE, Gullet J, Mehalko SG, Gordon SM, Owen WF, Matthews TR, Buhles WC & De Armond B (1991) Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. Journal of Infectious Diseases 163:716-719.
5. Ence A, Chou S, Biron KK, Stanat SC, Balfour HH & Jordan MC (1989) Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. New England Journal of Medicine 320:289-293.
6. Häbich D, Schulze TJ, Reefschläger J, Hansen J, Neumann R, Streissle G & Paessens A (1994) Novel pseudopeptides with antiviral activity. European Patent Application 646597 31.8.1994, Bayer AG.
7. Iizuka K, Kamijo T, Harada H, Akahane K, Kubota T, Umeyama H, Ishida T & Kiso Y (1990) Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction. Journal of Medical Chemistry 33:2707-2714.
8. Kern ER, Richards JT, Katz ME & Overall JC (1984) Murine Cytomegalovirus infection as a model for determining potential efficacy of antivirals in human disease. Birth Defects Original Article Series 20:421-423.
9. Kern ER (1991) Value of animal models to evaluate agents with potential activity against human cytomegalovirus. Transplant Proceedings 23 (Suppl. 3):152-155.
10. Knox K, Dobryski W & Carrigan D (1991) Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 337:1292-1293.
11. Lucia HL, Griffith BP & Hsiung GD (1984) Effect of acyclovir and phosphonoformate on cytomegalovirus infection in guinea pigs. Intervirology 21:141-149.
12. Malcom BA, Lowe C, Shechosky S, McKay RT, Yang C, Shah V, Simon R, Vederas JC & Santi DV (1995) Peptide aldehyde inhibitors of hepatitis A virus 3C proteinase. Biochemistry 34:8172-8179.
13. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M & Weissman IL (1988) The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241:1632-1639.
14. Mocarski ES, Bonyhadi M, Salimi S, McCune JM & Kaneshima H (1993) Human cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication. Proceedings of the National Academy of Sciences, USA 90:104-108.
15. Neyts J, Balzarini J, Naesens L & De Clercq E (1992) Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. Journal of Medicinal Virology 37:67-71.
16. Neyts J, Stals F, Bruggeman C & De Clercq E (1993) Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo. European Journal of Clinical Microbiology and Infectious Diseases 12:437-446.
17. Ogilvie W, Bailey M, Poupart MA, Abraham A, Bhavsar A, Bonneau P, Bousquet Y, Chabot C, Duceppe JS, Fazal G, Goulet S, Grand-Maitre C, Guse I, Halmos T, Lavallee P, Leach M, Malenfant E, O'Meara J, Plante R, Plouffe C, Poirer M, Soucy F, Yoakim C & Deziel R (1997) Peptidornimetic inhibitors of the cytomegalovirus protease. Journal of Medicinal Chememistry 40:4113-4135.
18. Rubin RH (1990) Impact of cytomegalovirus infection on organ transplant recipients. Review of Infectious Diseases 12 (Suppl. 7):754-766.
19. Sanderson PEJ & Naylor-Olsen AM (1998) Throbin inhibitor design. Current Medical Chemistry 5:289-304.
20. Smee DF, Barnett BB, Sidwell RW, Reist EJ & Holy A (1995) Antiviral activities of nucleosides and nucleotides against wild-type and drug-resistant strains of murine cytomegalovirus. Antiviral Research 26:1-9.
21. Stagno S, Pass RF, Dworksky ME, Henderson RE, Moore EG, Walton PD & Alford CD (1982) Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infections. New England Journal of Medicine 306:945-949.
22. Tyms AS, Taylor DL & Parkin JM (1989) Cytomegalovirus and the acquired immunodeficiency syndrome. Journal of Antimicrobal Chemotherapy 23 (Suppl. A):89-105.
23. Yang H, Drain RL, Franco ChA & Clark JM (1996) Efficacy of BMS-180194 against experimental cytomegalovirus infections in immunocompromised mice. Antiviral Research 29:233-241.